FR Regulatory | 22 July 2025 07:02
Sartorius Stedim Biotech SA: Information on Document Availability
|
Sartorius Stedim Biotech SA
Aubagne, July 22, 2025
Information on Document AvailabilityThe report on the first half 2025 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: It contains the following information:
A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 petra.mueller2@sartorius.com
Regulatory filing PDF file File: 2025_SSB_Document availability H1_en |
|
|
|
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report |
| EQS News ID: | 2172692 |
| End of Announcement | EQS News Service |
|
|
2172692 22-Jul-2025 CET/CEST